UBS Maintains Buy on Medline, Lowers Price Target to $43

Benzinga Newsdesk www.benzinga.com Negative 67.1%

Neg 67.1% Neu 0% Pos 0%

UBS analyst Kevin Caliendo maintains Medline (NASDAQ:MDLN) with a Buy and lowers the price target from $45 to $43.

Comments

No comments yet. Be the first!